Home >> Research Area >>Natural Products>>Triterpenoids>> 20,24-Dihydroxydammar-25-en-3-one

20,24-Dihydroxydammar-25-en-3-one

CAS# 75069-59-9

20,24-Dihydroxydammar-25-en-3-one

Catalog No. BCN4302----Order now to get a substantial discount!

Product Name & Size Price Stock
20,24-Dihydroxydammar-25-en-3-one:5mg Please Inquire In Stock
20,24-Dihydroxydammar-25-en-3-one:10mg Please Inquire In Stock
20,24-Dihydroxydammar-25-en-3-one:20mg Please Inquire In Stock
20,24-Dihydroxydammar-25-en-3-one:50mg Please Inquire In Stock

Quality Control of 20,24-Dihydroxydammar-25-en-3-one

Number of papers citing our products

Chemical structure

20,24-Dihydroxydammar-25-en-3-one

3D structure

Chemical Properties of 20,24-Dihydroxydammar-25-en-3-one

Cas No. 75069-59-9 SDF Download SDF
PubChem ID 21607677 Appearance Powder
Formula C30H50O3 M.Wt 458.7
Type of Compound Triterpenoids Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name (5R,8R,9R,10R,13R,14R,17S)-17-[(2S,5S)-2,5-dihydroxy-6-methylhept-6-en-2-yl]-4,4,8,10,14-pentamethyl-1,2,5,6,7,9,11,12,13,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
SMILES CC(=C)C(CCC(C)(C1CCC2(C1CCC3C2(CCC4C3(CCC(=O)C4(C)C)C)C)C)O)O
Standard InChIKey WLFYAHQFDJKVSZ-QCIZWGLLSA-N
Standard InChI InChI=1S/C30H50O3/c1-19(2)22(31)12-18-30(8,33)21-11-16-28(6)20(21)9-10-24-27(5)15-14-25(32)26(3,4)23(27)13-17-29(24,28)7/h20-24,31,33H,1,9-18H2,2-8H3/t20-,21+,22+,23+,24-,27+,28-,29-,30+/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of 20,24-Dihydroxydammar-25-en-3-one

The barks of Ailanthus altissima

Protocol of 20,24-Dihydroxydammar-25-en-3-one

Structure Identification
Chemistry of Natural Compounds, 1991, 27(5):588-592.

Crystal and molecular structure of 20S,24S-dihydroxydammar-25-en-3-one.[Reference: WebLink]


METHODS AND RESULTS:
The complete spatial structure of 20S,24S-dihydroxydammar-25-en-3-one(20,24-Dihydroxydammar-25-en-3-one) — a triterpenoid isolated from the leaves of a Far-Eastern species of birch,Betula mandschurica — has been established.
CONCLUSIONS:
Intermolecular cooperative hydrogen bonds that are unusual for a triterpenoid system have been detected in crystals of 20S,24S-dihydroxydammar-25-en-3-one(20,24-Dihydroxydammar-25-en-3-one), with the participation of both hydroxy groups in one chain of bonds and an orientation of the associated molecules that is characteristic for a bimolecular layer.

20,24-Dihydroxydammar-25-en-3-one Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

20,24-Dihydroxydammar-25-en-3-one Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 20,24-Dihydroxydammar-25-en-3-one

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1801 mL 10.9004 mL 21.8007 mL 43.6015 mL 54.5019 mL
5 mM 0.436 mL 2.1801 mL 4.3601 mL 8.7203 mL 10.9004 mL
10 mM 0.218 mL 1.09 mL 2.1801 mL 4.3601 mL 5.4502 mL
50 mM 0.0436 mL 0.218 mL 0.436 mL 0.872 mL 1.09 mL
100 mM 0.0218 mL 0.109 mL 0.218 mL 0.436 mL 0.545 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on 20,24-Dihydroxydammar-25-en-3-one

Antiviral activity of 20(R)-ginsenoside Rh2 against murine gammaherpesvirus.[Pubmed:29021696]

J Ginseng Res. 2017 Oct;41(4):496-502.

BACKGROUND: Ginsenosides are the major components of Panax ginseng Meyer, an herbal medicine used for the treatment of various diseases. Different ginsenosides contribute to the biological properties of ginseng, such as antimicrobial, anticancer, and immunomodulatory properties. In this study, we investigated the antiviral effects of 15 ginsenosides and compound K on gammaherpesvirus. METHODS: The antiviral activity of ginsenosides was examined using the plaque-forming assay and by analyzing the expression of the lytic gene. RESULTS: 20(R)-Ginsenoside Rh2 inhibited the replication and proliferation of murine gammaherpesvirus 68 (MHV-68), and its half-maximal inhibitory concentration (IC50) against MHV-68 was estimated to be 2.77 muM. In addition, 20(R)-ginsenoside Rh2 inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced lytic replication of human gammaherpesvirus in the Kaposi's sarcoma-associated herpesvirus (KSHV)-positive cell line BC3. CONCLUSION: Our results indicate that 20(R)-ginsenoside Rh2 can inhibit the replication of mouse and human gammaherpesviruses, and thus, has the potential to treat gammaherpesvirus infection.

Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms: Randomised, double-blind, placebo-controlled trial.[Pubmed:29024410]

Clin Otolaryngol. 2018 Apr;43(2):496-501.

OBJECTIVES: Gastroesophageal reflux recommended treatment (dose and duration) with proton-pump inhibitor (PPI) compared to placebo significantly reduces the signs and symptoms of laryngopharyngeal reflux (LPR) and comorbid chronic rhinosinusitis (CRS). DESIGN: Double-blind randomised placebo-controlled trial. SETTING: Eight weeks of treatment with omeprazole 20 mg once daily (OD). PARTICIPANTS: Sixty patients (28 women, aged 19-87 years) with diagnosed LPR and comorbid CRS. MAIN OUTCOME MEASURES: Significant reduction in signs and symptoms (reflux symptom index (RSI) score as subjective, and reflux finding score (RFS) as objective measure) of LPR after 8 weeks of treatment with omeprazole 20 mg OD when compared to placebo. Secondary objectives were significant reduction in signs and symptoms of comorbid CRS after 8 weeks of treatment with omeprazole 20 mg OD when compared to placebo and the association of the severity of signs and symptoms of LPR with the ones of CRS. RESULTS: RSI and RFS decreased significantly more in the active treatment group after 8 weeks compared to placebo (P < .001 for both). CRS and endoscopy scoring decreased both significantly more in the active group after 8 weeks compared to placebo (P < .001 for both). CRS scoring significantly correlated with RSI (R = 0.312, P = .015) but not with RFS (R = 0.199, P = .127). CONCLUSIONS: The results of our trial suggest that omeprazole 20 mg OD for 8 weeks was effective in reducing signs and symptoms of both LPR and CRS, although in most patients still present at the end of the trial.

Baeyer-Villiger reaction of steroid sapogenins by CF3COOH-H2O2. A short cut to pregnan-3beta,16beta,20-triol 3-monoacetates.[Pubmed:29024671]

Steroids. 2017 Dec;128:1-5.

Treatment of steroid sapogenins with H2O2 in CF3COOH for 15min followed by reflux in CH3OH/H2O afforded good yields of pregnan-3beta,16beta,20-triol 3-monoacetates. When the hydrolysis step was carried out with KOH in refluxing methanol excellent yields pregnantriols were obtained. The resulting compounds were characterized by their melting points and NMR spectral data. An X-ray diffraction analysis of compound 3a confirmed the proposed structure and provided detailed information about the bond lengths, bond angles and conformation.

Keywords:

20,24-Dihydroxydammar-25-en-3-one,75069-59-9,Natural Products, buy 20,24-Dihydroxydammar-25-en-3-one , 20,24-Dihydroxydammar-25-en-3-one supplier , purchase 20,24-Dihydroxydammar-25-en-3-one , 20,24-Dihydroxydammar-25-en-3-one cost , 20,24-Dihydroxydammar-25-en-3-one manufacturer , order 20,24-Dihydroxydammar-25-en-3-one , high purity 20,24-Dihydroxydammar-25-en-3-one

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: